Recent Updates — RAJAF

TFA Therapeutics, Inc. announced the approval and authorization of an offshore private placement offering up to $15 million in aggregate proceeds through rolling closings. The company is issuing ordinary shares at a fixed subscription price of $2.52 per share, targeting approximately $10 million from roughly 3.97 million shares, with a maximum capacity of 5.95 million shares. Proceeds are intended to advance the development and regulatory activities of TFA-01, including chemistry, manufacturing, controls, nonclinical safety, clinical trials, and working capital needs. The offering is conducted exclusively with non-U.S. persons in offshore transactions pursuant to Regulation S, with no directed selling efforts in the United States. TFA Therapeutics operates in the biotechnology industry, focusing on drug development.

On July 12, 2026, shareholders of TFA Therapeutics, Inc. (formerly Cordyceps Sunshine Biotech Holdings Co., Ltd.) approved a special resolution to change the company's name. The company completed the filing of the certificate of incorporation on change of name with the Cayman Islands Registry of Companies on July 20, 2026, and received the completed certificate on July 22, 2026. The ticker symbol remains unchanged. TFA Therapeutics, Inc. is a biotechnology company.